Saif Elamin1, Nikita Rajiv Bhatt2, Niall F Davis3, Paul Sweeney4. 1. Registrar, Department of Urology, Mercy University Hospital , Cork, Ireland . 2. SHO, Department of Urology, University Hospital Limerick, Ireland . 3. Specialist Regiatrar, Department of Urology, St. Vincent's University Hospital , Dublin, Ireland . 4. Consultant Urologist, Department of Urology, Mercy University Hospital , Cork, Ireland .
Abstract
INTRODUCTION: Considerable Proportion of Prostate Cancer (PCa) patients suitable for Active Surveillance (AS) harbour aggressive disease at surgical histopathology. Identification of truly indolent prostate cancer at diagnosis is difficult. AIM: Of this study was to evaluate the accuracy of current AS protocols in identifying low risk PCa by comparing the histopathology at biopsy and surgery. MATERIALS AND METHODS: A retrospective study was performed on all patients who underwent Radical Prostatectomy (RP) between 2008 and 2012. We identified patients who fulfilled inclusion criteria of five different established AS protocols. Histopathology at biopsy was compared with final surgical histopathology to identify upgrading or upstaging of disease. The biochemical recurrence rate in the cohort was also determined. RESULTS: A total of 59 patients (24%) met criteria of at least one protocol. Sixteen patients (28%) were eligible for AS based on all studied criteria. Overall 24 patients (40.6%) were upgraded in their final histopathology while 12 patients (20%) upstaged from their original TRUS biopsy. Two patients (3%) had PSA failure, both had salvage radiotherapy. CONCLUSION: There is considerable discrepency in current AS selection criteria which makes it necessary to introduce novel markers to identify indolent disease as a part of AS protocol for PCa.
INTRODUCTION: Considerable Proportion of Prostate Cancer (PCa) patients suitable for Active Surveillance (AS) harbour aggressive disease at surgical histopathology. Identification of truly indolent prostate cancer at diagnosis is difficult. AIM: Of this study was to evaluate the accuracy of current AS protocols in identifying low risk PCa by comparing the histopathology at biopsy and surgery. MATERIALS AND METHODS: A retrospective study was performed on all patients who underwent Radical Prostatectomy (RP) between 2008 and 2012. We identified patients who fulfilled inclusion criteria of five different established AS protocols. Histopathology at biopsy was compared with final surgical histopathology to identify upgrading or upstaging of disease. The biochemical recurrence rate in the cohort was also determined. RESULTS: A total of 59 patients (24%) met criteria of at least one protocol. Sixteen patients (28%) were eligible for AS based on all studied criteria. Overall 24 patients (40.6%) were upgraded in their final histopathology while 12 patients (20%) upstaged from their original TRUS biopsy. Two patients (3%) had PSA failure, both had salvage radiotherapy. CONCLUSION: There is considerable discrepency in current AS selection criteria which makes it necessary to introduce novel markers to identify indolent disease as a part of AS protocol for PCa.
Authors: Ryan K Berglund; Timothy A Masterson; Kinjal C Vora; Scott E Eggener; James A Eastham; Bertrand D Guillonneau Journal: J Urol Date: 2008-09-17 Impact factor: 7.450
Authors: Mark S Soloway; Cynthia T Soloway; Ahmed Eldefrawy; Kristell Acosta; Bruce Kava; Murugesan Manoharan Journal: Eur Urol Date: 2010-08-20 Impact factor: 20.096
Authors: Mark Louie-Johnsun; Mischel Neill; Karien Treurnicht; Michael Jarmulowicz; Christopher Eden Journal: BJU Int Date: 2009-05-07 Impact factor: 5.588
Authors: Roderick C N van den Bergh; Hashim U Ahmed; Chris H Bangma; Matthew R Cooperberg; Arnauld Villers; Christopher C Parker Journal: Eur Urol Date: 2014-01-28 Impact factor: 20.096
Authors: Daniel W Lin; E David Crawford; Thomas Keane; Brent Evans; Julia Reid; Saradha Rajamani; Krystal Brown; Alexander Gutin; Jonathan Tward; Peter Scardino; Michael Brawer; Steven Stone; Jack Cuzick Journal: Urol Oncol Date: 2018-04-11 Impact factor: 3.498
Authors: Katerina Pestova; Adam J Koch; Charles P Quesenberry; Jun Shan; Ying Zhang; Amethyst D Leimpeter; Beth Blondin; Svetlana Sitailo; Lela Buckingham; Jing Du; Huixin Fei; Stephen K Van Den Eeden Journal: BMC Cancer Date: 2018-01-02 Impact factor: 4.430